• Протек
    LEADERSHIP
    THROUGH PARTNERSHIP
  • Протек 2
    LEADERSHIP
    THROUGH PARTNERSHIP
  • Протек 4
    LEADERSHIP
    THROUGH PARTNERSHIP

PROTEK Group is one of the largest pharmaceutical companies in Russia.

PROTEK Group was established in 1990. In 30 years the small company has become the largest Russian pharmaceutical holding, has overcome various development stages, including formation of CV PROTEK distribution business, development of retail pharmacy chain Rigla and expansion of Sotex production.

Crucial development stage of the company manifested itself in entry to public capital market by means of IPO in 2010.

Currently, PROTEK Group has a diversified business structure, and is present in all main segments of pharmaceutical industry:

  • • production of medicinal products (Sotex, PharmFirm JSC Rafarma);
  • • distribution of pharmaceutical products and beauty and wellness products (CV PROTEK);
  • • retail trade (pharmacy chain Rigla).

The total number of the group’s employees exceeds than 17 thousand people. According to half-year 2019 results, consolidated revenue of CV PROTEK amounted to 125,161 mln RUB (audit data).

The practice of the Group business is focused both on increasing the competitiveness and sustainability of the Group unified business. In its development, PROTEK focuses on technological effectiveness and innovations.

For PROTEK Group, principle of transparency and publicity is the top priority. The Group pursues reasonable credit and financial policy and adheres to International Financial Reporting Standards (IFRS). Since 2010, PROTEK is a public company; PROTEK shares are traded at MICEX Stock Exchange.


Zdravcity is at the top of the rating of associations and online resources of pharmaceutical retail business by the rates of growth

The gross sales amount of the online resource was equal to more than 6 billion rubles.

more...

Zdravcity is among the ten finalists of the “Runet Prize”

The short list of the prize, formed according to the results of voting of the Expert Board, was announced on 1 ... more...

Sotex introduces low molecular weight heparin (nadroparin) under the Detrombin® trademark

The company is strengthening its position in the parenteral anticoagulant market by expanding its product line. more...

CV Protek uses cookies (files with data about previous visits to the site) for personalization of services and convenience of users. CV Protek is serious about protecting personal data. Read the terms and principles of data processing. .
You can prevent cookies from being stored in your browser settings.
Close